| |
|
|
|
Xtalks, Online
2024-12-11
The development and approval of chimeric antigen receptor (CAR) T-cell therapies to treat several B-cell-derived hematologic malignancies has been recognized as a significant advance in clinical treatment.
Solid tumors represent 90 percent of all adult cancers. Therefore, there is an urgent need to tackle current obstacles to cell therapy development in this space. Key challenges include the hostile tumor microenvironment (TME) and a lack of effective cell therapy penetration and persistence in solid tumors.
To address these challenges, methods that can generate more potent cell populations during drug discovery and subsequently translate to the manufacturing process must be investigated. In this webinar, data from a series of projects focused on the improvement of cell and gene therapy (CGT) safety and efficacy are discussed.
A comparison of the phenotype and performance of cancer cell lines and CAR T-cells grown in conventional culture conditions with those grown in conditions that more closely resemble the TME was undertaken using the AVATARTM Odyssey system from Xcell Biosciences (Xcellbio). Cells were cultured and grown under regulated conditions, including modified oxygen and pressure levels, while adhering to established protocols for cell therapy development, with no special techniques needed for cell growth. The resulting cells are thought to undergo metabolic reprogramming which may increase cell killing properties and lead to better anti-tumor activity. Data and insights from this work will be shared.
Register for this webinar today to explore cutting-edge advancements in CAR T-cell therapies aimed at overcoming key challenges in treating solid tumors.
Keywords: Cancer, Drug Development, Oncology, CAR-T, CAR-T Immunotherapy, Oncology Trials, Oncology Clinical Trials, Therapeutic Areas, CAR T-Cell Therapy, Cell & Gene Therapies, Basic Research
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
James Lim, PhD, Chief Scientific Officer, Xcell Biosciences
Ningchun Liu, PhD, Director of Enterprise Cell and Gene Therapy, Labcorp
Anita J. Zaitouna, PhD, Scientist, Scientific Development, Assay Development (Research), Labcorp
Dr. Maryland Franklin, PhD, Vice President and Enterprise Head, Cell and Gene Therapy, Labcorp
Brian Feth, Co-founder and CEO, Xcell Biosciences
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2024-12-11
|
|
|
|
|
|
|
|
Registration:
|
|
Free Registration
|
|
|
E-mail:
|
|
tristan@xtalks.com
|
|
|
|
|
|
|
|
|